Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2010

Nacalai to Provide TriLink’s Nucleic Acid Products in Certain Asian Countries

  • Nacalai USA has obtained distribution rights for TriLink BioTechnologies’ modified nucleic acid products in Japan, Singapore, South Korea, and Taiwan. The firm manufactures custom oligonucleotides, modified nucleoside triphosphates, and CleanAmp™ PCR products for the diagnostic and OEM markets.

    TriLink performs custom oligo synthesis and modifications for diagnostic and therapeutic development. It also stocks over 150 modified nucleoside triphosphates including Aminoallyl, Biotin, and 2' Fluoro nucleotides. In addition, it offers specialty modified nucleotides such as bisphosphates, a series of monophosphates, as well as CAP and mCAP.

    CleanAmp products include primers, dNTPs, and amidites. CleanAmp primers contain thermolabile chemical modifications that allow for primer-based Hot Start activation in PCR. These modifications prevent primer extension at the lower temperatures of PCR set-up and manipulation, according to TriLink. A Hot Start thermal activation step removes the modification and generates the corresponding unmodified primer, which supports amplification of the desired target.

    CleanAmp amidites allow a firm with its own oligo-synthesis capabilities to produce its own CleanAmp primers. They can reportedly be used on any DNA synthesizer.

    Founded in 1996 and based in San Diego, TriLink also offers custom chemistry, contract research services, and ISO/QSR compliant cGMP production facilities.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »